{"id":328137,"date":"2026-10-27T12:11:10","date_gmt":"2026-10-27T06:41:10","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=328137"},"modified":"2026-10-27T12:11:10","modified_gmt":"2026-10-27T06:41:10","slug":"active-ingredients-and-custom-synthesis-leader-global-generics-maker-and-chronic-therapy-brand-leader-stocks-roadmap-apex-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-synthesis-leader-global-generics-maker-and-chronic-therapy-brand-leader-stocks-roadmap-apex-list\/","title":{"rendered":"3 Active Ingredients and Custom Synthesis Leader, Global Generics Maker and Chronic Therapy Brand Leader Stocks With a Strong Future Roadmap: Divi’s Laboratories, Dr. Reddy’s Laboratories and Mankind Pharma"},"content":{"rendered":"

Divi’s Laboratories, Dr. Reddy’s Laboratories and Mankind Pharma: ROE of 11.1% to 15.3% and FY22 to FY26 revenue CAGR of 5.1% to 16.4%. Prices as of 26 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three ingredient, generics and brand pharma stocks to watch are Divi’s Laboratories, Dr. Reddy’s Laboratories and Mankind Pharma. Their return on equity ranges from 11.1% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 16.4%. Divi’s Laboratories has the highest return on equity at 15.3%, while Mankind Pharma has the fastest revenue growth at 16.4% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

Ingredient, generics and brand pharma stocks offer a focused view of a sector where demand keeps widening. Divi’s Laboratories, Dr. Reddy’s Laboratories and Mankind Pharma cover an active ingredients and custom synthesis leader, a global generics maker and a chronic therapy brand leader.<\/p>\n

This list covers three ingredient, generics and brand pharma stocks with complete current figures: Divi’s Laboratories, Dr. Reddy’s Laboratories and Mankind Pharma. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n